HDAC Activity in Peripheral Skeletal Muscle in COPD

COPD Clinical Trial

Official title: The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD

Status Completed

Clinical Trial Summary

We wish to study the effect of Chronic Obstructive Pulmonary Disease on the activity of the nuclear transcription pathway in peripheral skeletal muscle to determine whether altered activity of this pathway may be responsible for the muscle dysfunction observed in these patients.

Clinical Trial Description

Peripheral muscle dysfunction is well recognised in COPD. We wish to study patients who we have found to have weak quadriceps muscles and study the molecular mechanisms underlying this problem. Patients will be well characterised with regard to their physiologic parameters and quadriceps muscle biopsies will be taken. These biopsy samples will be analysed with respect to NFkappaB activity and HDAC activity by nuclear extraction and for muscle inflammatory cytokines. We know that in the lung tissue of COPD patients there is evidence of a reduction in HDAC activity which might be responsible for the higher levels of pronflammatory cytokines in the lung. We will also study a healthy control group and a small selection of patients who are in respiratory failure due to idiopathic scoliosis in the same way. ;

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• COPD

• NCT number: NCT00180752
• Study type: Observational
• Source: Imperial College London
• Status: Completed
• Phase: N/A
• Start date: September 2005
• Completion date: August 2008